Tenovin‐6 (a small‐molecule inhibitor of SIRT1 and SIRT2) treatment yielded a significant loss of imatinib‐resistant chronic myeloid leukemia (CML) CD34+ stem cells in vivo. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.